IKT — Inhibikase Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$2.48
+$0.10 (+3.99%)
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on NASDAQ. It is led by Mark T. Iwicki, based in 1000 N. West Street, Wilmington, DE, United States, 19801, with about 35 employees. Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Latest reported IKT revenue for 2025-09-30 was $0. Net income was -$11.9M. IKT currently screens at market cap $215.2M.
Use this IKT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IKT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IKT SEC filings page. Lician reads the product cache first so this HTML stays unique to Inhibikase Therapeutics Inc even when a live quote feed is slow.
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Key Statistics
Market Cap
$215.21M
Volume
244,018
Previous Close
$2.50
Day Range
$2.43 – $2.51
EPS
-$1.16
Revenue
$0.00
Net Income
-$27.52M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
35
IKT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $260.50K | $123.44K | $3.10M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$27.52M | -$19.03M | -$18.05M | -$14.79M |
| EPS (Diluted) | -$1.16 | -$3.16 | -$4.28 | -$0.81 |
Total Assets
$98.60M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$56.50M
Operating Cash Flow
-$19.15M
Free Cash Flow
$0.00
Inhibikase Therapeutics Inc Company Information
- CEO & Director
- Mark T. Iwicki
- Headquarters
- 1000 N. West Street, Wilmington, DE, United States, 19801
- Website
- www.inhibikase.com
- Phone
- 302 295 3800
- IPO / Founded
- 2020-12-23
- Sector
- Healthcare
- Industry
- Biotechnology